Salute e Benessere

Veterinary Ultrasound Market to Reach USD 539 Million by 2029: Trends, Drivers…

Browse in-depth TOC on "Veterinary Ultrasound Market" Browse in-depth TOC on "Veterinary Ultrasound Market" 230 - Tables 52 - Figures 250 - Pages Key Drivers and Challenges Factors propelling market growth include increasing pet ownership and healthcare spending, advancements in technology, growing awareness of animal health, and rising livestock populations. Challenges include the high cost of advanced devices, scarcity of skilled professionals, economic constraints in...

Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa

Bavarian Nordic is committed to support global efforts to address the mpox situation in Africa through a donation of 15,000 doses of mpox vaccineEmergency Use Authorization for the MVA-BN vaccine has been issued in the DR CongoCOPENHAGEN, Denmark, June 28, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced an extended commitment to help fight the current mpox outbreak in Africa. The Company's MVA-BN vaccine, the only FDA and EMA-approved mpox vaccine, which served as an important...

Roche's Vabysmo gets CHMP recommendation for third indication retinal vein…

Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to aflibercept If approved, Vabysmo would be the first and only bispecific antibody treatment available for the nearly one million people with RVO in the European UnionVabysmo is already approved in the US and Japan for RVO and in more than 95 countries around the world for people living with nAMD...

Endo Announces Commencement of OTCQX Trading

The OTCQX Market offers a valuable and convenient trading experience for U.S. investors, brokers and institutions. It is the premier market of OTC Markets Group, which is designed for established, investor-focused companies worldwide. Eligibility for trading on this platform requires companies to fulfill stringent financial and governance standards, adhere to U.S. securities laws, and maintain transparent and current disclosure. The OTCQX Market offers a valuable and convenient trading…

CHMP recommends EU approval of Roche's PiaSky for people with PNH, a rare…

If approved, PiaSky will be the first monthly subcutaneous (SC) treatment for paroxysmal nocturnal haemoglobinuria (PNH) in the EU Additionally, with the option to self-administer, PiaSky may provide an alternative to existing intravenous (IV) C5 inhibitors, potentially helping to reduce treatment burden 1 The recommendation is based on the COMMODORE 2 study results, where SC PiaSky given every month demonstrated equivalent disease control and comparable safety to IV eculizumab...

AB Science provides an update on the application for conditional marketing…

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSISParis, 28 June, 2024, 12:30pm CETAB Science SA(Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted, in line with the trend vote, a negative opinion on the application for conditional marketing authorization of...

SPINEART APPOINTS LAURENT NODÉ-LANGLOIS AS CHIEF TECHNOLOGY OFFICER TO LEAD…

Laurent joins Spineart with over 25 years of experience in biomechanics, surgical navigation, innovation and intellectual property. Prior to joining Spineart, he served as Managing Director at General Electric, playing a pivotal role in advancing GE Healthcare's 3D imaging and navigation technologies. Laurent joins Spineart with over 25 years of experience in biomechanics, surgical navigation, innovation and intellectual property. Prior to joining Spineart, he served as Managing Director at...

SciBase partner with a large health care group in Los Angeles, Unified Health…

"SciBase and Unified Health are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes," says Pia Renaudin, CEO of SciBase. "We are encouraged to see more patients getting access to our point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable." "SciBase and Unified Health are well aligned with a shared mission to provide clinicians…

Zealand Pharma completes registration of capital increase

Company announcement – No. 36 / 2024 Zealand Pharma completes registration of capital increaseNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SECURITIES IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT...

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of…

Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ®NHL-1 studyFL is the second most common type of NHL and accounts for approximately 20-30 percent of all global casesIf approved, epcoritamab (TEPKINLY ® ) would become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after...

Gerresheimer: New pictures available

Media Contact Media Contact Jutta LorbergHead of Corporate CommunicationT +49 211 6181 [email protected] View original content: https://www.prnewswire.co.uk/news-releases/gerresheimer-new-pictures-available-302184778.html

Hansa Biopharma: increase in number of shares and votes

This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons below, on June 28, 2024 at 07:00 CEST. This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through...

BioSenic S.A. : Information on the total number of voting rights and shares

PRESS RELEASE – REGULATED INFORMATIONMont-Saint-Guibert, Belgium, June 28, 2024, 7.00 am CET –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication...

Natalia Vodianova Invests in Swiss Beauty and Longevity Brand NIANCE

NIANCE is a Zurich-based luxury skincare and nutritional supplement brand, Switzerland's best-kept secret in beauty and longevity. Celebrated for its groundbreaking biotechnology, FERNESSE™, this technology enables the release of the full Triple-Biotic power (prebiotics, probiotics, and postbiotics) of its active ingredients, significantly increasing the bioavailability of nutrients. By addressing the root cause of aging, NIANCE combines the finest natural ingredients from the Swiss Alps with…

Dioseve Completes Funding Round, Raising a Total of 7 Million USD

*1. The Common name for the "ASKA Innovation Investment Limited Partnership," co-managed by ASKA Pharmaceutical Co., Ltd. and Future Venture Capital Co., Ltd. *1. The Common name for the "ASKA Innovation Investment Limited Partnership," co-managed by ASKA Pharmaceutical Co., Ltd. and Future Venture Capital Co., Ltd. *2. The Common name for the "Hokuriku Regional Venture Investment Limited Partnership," co-managed by QR Investment Inc. (a subsidiary of Hokugin…

Leqembi® (lecanemab) launched in China

In China, Leqembi will first be launched in the private market and the price for a 200 mg vial will be CNY 2,508. In collaboration with Eisai, a major Chinese medical insurance company has developed and launched a healthcare insurance plan specifically for AD including partial coverage of the drug cost. Through these efforts, Eisai is committed to promoting the early detection, diagnosis, and treatment of AD in China. InChina, Leqembi will first be launched in the private market and the...

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer's Disease Launched in…

China is the Third Country to Launch LEQEMBI Following the United States and Japan TOKYO and CAMBRIDGE, Mass., June27, 2024(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI ® ” (brand name in China: “乐意保 ® ”, generic name:...

Systemic Sclerosis Market to Exhibit Significant Growth by 2034, Predicts…

Key Takeaways from the Systemic Sclerosis Market Report Key Takeaways from the Systemic Sclerosis Market Report Discover which therapies are expected to grab the major systemic sclerosis market share @Systemic Sclerosis Market Report Systemic Sclerosis Overview Systemic sclerosis, also known as scleroderma, is a chronic autoimmune disease characterized by the hardening and tightening of the skin and connective tissues. The condition arises due to the overproduction and...

Completion of Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2024. On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program was expected to be completed no later than December 16, 2024.The following transactions were executed under the program from June 24, 2024, to June 26, 2024: ...

Inside Information: Update for Bioretec's RemeOs™ Trauma Screw European…

Further enquiries Further enquiries Alan Donze, CEO, tel. +358 40 663 5011 Johanna Salko, CFO, tel. +358 40 754 8172 Certified advisor Nordic Certified Adviser AB, +46 70 551 67 29 Bioretec in brief Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate...

American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech…

The article continued: According to the World Health Organization, the global cancer burden is growing amidst a mounting need for services. As well, an alarming trend is emerging, where cancer cases in younger people are rising sharply. The article continued: According to theWorld Health Organization, theglobal cancer burden is growing amidst a mounting need for services. As well, analarming trend is emerging, where cancer cases in younger people are rising sharply. Oncolytics...

Nicox: 2024 Ordinary Shareholder Meeting

Press ReleaseNicox: 2024 Ordinary Shareholder MeetingJune 27, 2024 – release at 17:30 CETSophia Antipolis, France Nicox SA(Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary general meeting convened on first call on Friday June 28, 2024, will not be held as the quorum required by law has not been reached.The shareholders of Nicox are thus convened on second call for an Ordinary general meeting on the...

New Board of RADAS, UAB

Additional Information MAXIMA GRUPĖ, UAB manages retail chains "Maxima" (in the Baltic countries), "Stokrotka" (in Poland), "T Market" (in Bulgaria), and the online food store "Barbora," operating in the Baltic countries. MAXIMA GRUPĖ, UAB is part of the "Vilniaus prekyba" group of companies. Through its other subsidiary companies, "Vilniaus prekyba" controls investments in retail and pharmacy chains, as well as real estate development…

IoT in Healthcare Market: Digitization Surge to Propel Valuation Beyond $926.9B…

Download a detailed overview:https://www.skyquestt.com/sample-request/iot-in-healthcare-market Download a detailed overview: https://www.skyquestt.com/sample-request/iot-in-healthcare-market IoT In Healthcare Market Overview: Segments covered in IoT in Healthcare Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/iot-in-healthcare-market Hospitals to Remain at the Top in Terms of IoT in Healthcare Adoption...

Altri Comunicati